[1] L. Dion, I. Carton, S. Jaillard, K. Nyangoh Timoh, S. Henno, H. Sardain, F. Foucher, J. Leveque, T. de la Motte Rouge, S. Brousse, V. Lavoue, The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer, J Clin Med, 9 (2020).
[2] A. Davis, A.V. Tinker, M. Friedlander, "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?, Gynecol Oncol, 133 (2014) 624-631.
[3] A.E. Freimund, J.A. Beach, E.L. Christie, D.D.L. Bowtell, Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer, Hematol Oncol Clin North Am, 32 (2018) 983-996.
[4] K.L. Lloyd, I.A. Cree, R.S. Savage, Prediction of resistance to chemotherapy in ovarian cancer: a systematic review, BMC Cancer, 15 (2015) 117.
[5] W. Kalow, Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine, Pharmacogenomics J, 6 (2006) 162-165.
[6] M. Binju, M.A. Padilla, T. Singomat, P. Kaur, Y. Suryo Rahmanto, P.A. Cohen, Y. Yu, Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review, Biochim Biophys Acta Gen Subj, 1863 (2019) 371-378.
[7] D. Spentzos, D.A. Levine, S. Kolia, H. Otu, J. Boyd, T.A. Libermann, S.A. Cannistra, Unique gene expression profile based on pathologic response in epithelial ovarian cancer, J Clin Oncol, 23 (2005) 7911-7918.
[8] M. Bernardini, C.H. Lee, B. Beheshti, M. Prasad, M. Albert, P. Marrano, H. Begley, P. Shaw, A. Covens, J. Murphy, B. Rosen, S. Minkin, J.A. Squire, P.F. Macgregor, High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer, Neoplasia, 7 (2005) 603-613.
[9] Y. Chen, F. Bi, Y. An, Q. Yang, Coexpression network analysis identified Kruppel-like factor 6 (KLF6) association with chemosensitivity in ovarian cancer, J Cell Biochem, (2018).
[10] L. Zhang, X. Zhang, S. Fan, Z. Zhang, Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis, Medicine (Baltimore), 98 (2019) e17803.
[11] M. Bagnoli, S. Canevari, D. Califano, S. Losito, M.D. Maio, F. Raspagliesi, M.L. Carcangiu, G. Toffoli, E. Cecchin, R. Sorio, V. Canzonieri, D. Russo, G. Scognamiglio, G. Chiappetta, G. Baldassarre, D. Lorusso, G. Scambia, G.F. Zannoni, A. Savarese, M. Carosi, P. Scollo, E. Breda, V. Murgia, F. Perrone, S. Pignata, L. De Cecco, D. Mezzanzanica, g. Multicentre Italian Trials in Ovarian cancer translational, Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study, Lancet Oncol, 17 (2016) 1137-1146.
[12] G. Benvenuto, P. Todeschini, L. Paracchini, E. Calura, R. Fruscio, C. Romani, L. Beltrame, P. Martini, A. Ravaggi, L. Ceppi, G. Sales, F. Donati, P. Perego, L. Zanotti, S. Ballabio, T. Grassi, M. Delle Marchette, G. Tognon, E. Sartori, M. Adorni, F. Odicino, M. D'Incalci, E. Bignotti, C. Romualdi, S. Marchini, Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer, Int J Cancer, 147 (2020) 565-574.
[13] J. Choi, D.G. Topouza, A. Tarnouskaya, S. Nesdoly, M. Koti, Q.L. Duan, Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer, BMC Cancer, 20 (2020) 413.
[14] W. Zhang, Y. Yu, F. Hertwig, J. Thierry-Mieg, W. Zhang, D. Thierry-Mieg, J. Wang, C. Furlanello, V. Devanarayan, J. Cheng, Y. Deng, B. Hero, H. Hong, M. Jia, L. Li, S.M. Lin, Y. Nikolsky, A. Oberthuer, T. Qing, Z. Su, R. Volland, C. Wang, M.D. Wang, J. Ai, D. Albanese, S. Asgharzadeh, S. Avigad, W. Bao, M. Bessarabova, M.H. Brilliant, B. Brors, M. Chierici, T.M. Chu, J. Zhang, R.G. Grundy, M.M. He, S. Hebbring, H.L. Kaufman, S. Lababidi, L.J. Lancashire, Y. Li, X.X. Lu, H. Luo, X. Ma, B. Ning, R. Noguera, M. Peifer, J.H. Phan, F. Roels, C. Rosswog, S. Shao, J. Shen, J. Theissen, G.P. Tonini, J. Vandesompele, P.Y. Wu, W. Xiao, J. Xu, W. Xu, J. Xuan, Y. Yang, Z. Ye, Z. Dong, K.K. Zhang, Y. Yin, C. Zhao, Y. Zheng, R.D. Wolfinger, T. Shi, L.H. Malkas, F. Berthold, J. Wang, W. Tong, L. Shi, Z. Peng, M. Fischer, Comparison of RNA-seq and microarray-based models for clinical endpoint prediction, Genome Biol, 16 (2015) 133.
[15] M. Hafner, N. Renwick, T.A. Farazi, A. Mihailovic, J.T. Pena, T. Tuschl, Barcoded cDNA library preparation for small RNA profiling by next-generation sequencing, Methods, 58 (2012) 164-170.
[16] N. Cancer Genome Atlas Research, Integrated genomic analyses of ovarian carcinoma, Nature, 474 (2011) 609-615.
[17] M.I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, 15 (2014) 550.
[18] P. Langfelder, S. Horvath, WGCNA: an R package for weighted correlation network analysis, BMC Bioinformatics, 9 (2008) 559.
[19] A.A. Shabalin, Matrix eQTL: ultra fast eQTL analysis via large matrix operations, Bioinformatics, 28 (2012) 1353-1358.
[20] L. Chang, G. Zhou, O. Soufan, J. Xia, miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology, Nucleic Acids Res, 48 (2020) W244-W251.
[21] E. Andres-Leon, G. Gomez-Lopez, D.G. Pisano, Prediction of miRNA-mRNA Interactions Using miRGate, Methods Mol Biol, 1580 (2017) 225-237.
[22] R.W. Tothill, A.V. Tinker, J. George, R. Brown, S.B. Fox, S. Lade, D.S. Johnson, M.K. Trivett, D. Etemadmoghadam, B. Locandro, N. Traficante, S. Fereday, J.A. Hung, Y.E. Chiew, I. Haviv, G. Australian Ovarian Cancer Study, D. Gertig, A. DeFazio, D.D. Bowtell, Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome, Clin Cancer Res, 14 (2008) 5198-5208.
[23] M. Bagnoli, L. De Cecco, A. Granata, R. Nicoletti, E. Marchesi, P. Alberti, B. Valeri, M. Libra, M. Barbareschi, F. Raspagliesi, D. Mezzanzanica, S. Canevari, Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients, Oncotarget, 2 (2011) 1265-1278.
[24] B. Gyorffy, A. Lanczky, Z. Szallasi, Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients, Endocr Relat Cancer, 19 (2012) 197-208.
[25] R. Aguirre-Gamboa, H. Gomez-Rueda, E. Martinez-Ledesma, A. Martinez-Torteya, R. Chacolla-Huaringa, A. Rodriguez-Barrientos, J.G. Tamez-Pena, V. Trevino, SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis, PLoS One, 8 (2013) e74250.
[26] H. Kim, A. Bhattacharya, L. Qi, Endoplasmic reticulum quality control in cancer: Friend or foe, Semin Cancer Biol, 33 (2015) 25-33.
[27] J. Tian, R. Liu, Q. Qu, Role of endoplasmic reticulum stress on cisplatin resistance in ovarian carcinoma, Oncol Lett, 13 (2017) 1437-1443.
[28] P. Bastola, L. Neums, F.J. Schoenen, J. Chien, VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal, Mol Oncol, 10 (2016) 1559-1574.
[29] N. Koundouros, G. Poulogiannis, Reprogramming of fatty acid metabolism in cancer, Br J Cancer, 122 (2020) 4-22.
[30] L.Y. Nie, Q.T. Lu, W.H. Li, N. Yang, S. Dongol, X. Zhang, J. Jiang, Sterol regulatory element-binding protein 1 is required for ovarian tumor growth, Oncol Rep, 30 (2013) 1346-1354.
[31] T. Porstmann, B. Griffiths, Y.L. Chung, O. Delpuech, J.R. Griffiths, J. Downward, A. Schulze, PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP, Oncogene, 24 (2005) 6465-6481.
[32] H.Q. Wang, D.A. Altomare, K.L. Skele, P.I. Poulikakos, F.P. Kuhajda, A. Di Cristofano, J.R. Testa, Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells, Oncogene, 24 (2005) 3574-3582.
[33] L.J. Wheeler, Z.L. Watson, L. Qamar, T.M. Yamamoto, B.T. Sawyer, K.D. Sullivan, S. Khanal, M. Joshi, V. Ferchaud-Roucher, H. Smith, L.A. Vanderlinden, S.W. Brubaker, C.M. Caino, H. Kim, J.M. Espinosa, J.K. Richer, B.G. Bitler, Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination, iScience, 19 (2019) 474-491.
[34] B.A.S. Pinto, L.M. Franca, F.R.M. Laurindo, A.M.A. Paes, Unfolded Protein Response: Cause or Consequence of Lipid and Lipoprotein Metabolism Disturbances?, Adv Exp Med Biol, 1127 (2019) 67-82.
[35] D. Hao, J. Liu, M. Chen, J. Li, L. Wang, X. Li, Q. Zhao, L.J. Di, Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity, Clin Cancer Res, 24 (2018) 3560-3571.
[36] N.R. Mahadevan, J. Rodvold, H. Sepulveda, S. Rossi, A.F. Drew, M. Zanetti, Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells, Proc Natl Acad Sci U S A, 108 (2011) 6561-6566.
[37] J.R. Cubillos-Ruiz, P.C. Silberman, M.R. Rutkowski, S. Chopra, A. Perales-Puchalt, M. Song, S. Zhang, S.E. Bettigole, D. Gupta, K. Holcomb, L.H. Ellenson, T. Caputo, A.H. Lee, J.R. Conejo-Garcia, L.H. Glimcher, ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis, Cell, 161 (2015) 1527-1538.
[38] D.L. Herber, W. Cao, Y. Nefedova, S.V. Novitskiy, S. Nagaraj, V.A. Tyurin, A. Corzo, H.I. Cho, E. Celis, B. Lennox, S.C. Knight, T. Padhya, T.V. McCaffrey, J.C. McCaffrey, S. Antonia, M. Fishman, R.L. Ferris, V.E. Kagan, D.I. Gabrilovich, Lipid accumulation and dendritic cell dysfunction in cancer, Nat Med, 16 (2010) 880-886.
[39] A. Wagschal, S.H. Najafi-Shoushtari, L. Wang, L. Goedeke, S. Sinha, A.S. deLemos, J.C. Black, C.M. Ramirez, Y. Li, R. Tewhey, I. Hatoum, N. Shah, Y. Lu, F. Kristo, N. Psychogios, V. Vrbanac, Y.C. Lu, T. Hla, R. de Cabo, J.S. Tsang, E. Schadt, P.C. Sabeti, S. Kathiresan, D.E. Cohen, J. Whetstine, R.T. Chung, C. Fernandez-Hernando, L.M. Kaplan, A. Bernards, R.E. Gerszten, A.M. Naar, Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis, Nat Med, 21 (2015) 1290-1297.
[40] Y.K. Adlakha, S. Khanna, R. Singh, V.P. Singh, A. Agrawal, N. Saini, Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRalpha expression and cholesterol homeostasis, Cell Death Dis, 4 (2013) e780.
[41] E.L. Hedditch, B. Gao, A.J. Russell, Y. Lu, C. Emmanuel, J. Beesley, S.E. Johnatty, X. Chen, P. Harnett, J. George, G. Australian Ovarian Cancer Study, R.T. Williams, C. Flemming, D. Lambrechts, E. Despierre, S. Lambrechts, I. Vergote, B. Karlan, J. Lester, S. Orsulic, C. Walsh, P. Fasching, M.W. Beckmann, A.B. Ekici, A. Hein, K. Matsuo, S. Hosono, T. Nakanishi, Y. Yatabe, T. Pejovic, Y. Bean, F. Heitz, P. Harter, A. du Bois, I. Schwaab, E. Hogdall, S.K. Kjaer, A. Jensen, C. Hogdall, L. Lundvall, S.A. Engelholm, B. Brown, J. Flanagan, M.D. Metcalf, N. Siddiqui, T. Sellers, B. Fridley, J. Cunningham, J. Schildkraut, E. Iversen, R.P. Weber, A. Berchuck, E. Goode, D.D. Bowtell, G. Chenevix-Trench, A. deFazio, M.D. Norris, S. MacGregor, M. Haber, M.J. Henderson, ABCA transporter gene expression and poor outcome in epithelial ovarian cancer, J Natl Cancer Inst, 106 (2014).
[42] L. Zheng, L. Li, Y. Lu, F. Jiang, X.A. Yang, SREBP2 contributes to cisplatin resistance in ovarian cancer cells, Exp Biol Med (Maywood), 243 (2018) 655-662.
[43] B. Li, H. Chen, N. Wu, W.J. Zhang, L.X. Shang, Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance, Int J Gynecol Cancer, 24 (2014) 1381-1388.
[44] Z. Amini-Farsani, M.H. Sangtarash, M. Shamsara, H. Teimori, MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway, Cytotechnology, 70 (2018) 203-213.
[45] J. Li, Q. Li, H. Huang, Y. Li, L. Li, W. Hou, Z. You, Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer, Int J Oncol, (2017).
[46] C. Sun, N. Li, B. Zhou, Z. Yang, D. Ding, D. Weng, L. Meng, S. Wang, J. Zhou, D. Ma, G. Chen, miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27(kip1.), Oncol Lett, 6 (2013) 507-512.
[47] R. Dai, J. Li, Y. Liu, D. Yan, S. Chen, C. Duan, X. Liu, T. He, H. Li, miR-221/222 suppression protects against endoplasmic reticulum stress-induced apoptosis via p27(Kip1)- and MEK/ERK-mediated cell cycle regulation, Biol Chem, 391 (2010) 791-801.
[48] Y. Zhang, J. Wu, J.Y. Liang, X. Huang, L. Xia, D.W. Ma, X.Y. Xu, P.P. Wu, Association of serum lipids and severity of epithelial ovarian cancer: an observational cohort study of 349 Chinese patients, J Biomed Res, 32 (2018) 336-342.
[49] A.J. Li, R.G. Elmore, I.Y. Chen, B.Y. Karlan, Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers, Gynecol Oncol, 116 (2010) 78-81.
[50] D.G. Topouza, J. Choi, S. Nesdoly, A. Tarnouskaya, C.J.B. Nicol, Q.L. Duan, Novel regulatory and transcriptional networks associated with resistance to platinum-based chemotherapy in ovarian cancer, bioRxiv, (2021).